CLINICAL TRIALS PROFILE FOR BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

505(b)(2) Clinical Trials for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03707795 ↗	Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study	Completed	Edward Kasaraskis	Early Phase 1	2017-08-21	By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
OTC	NCT03707795 ↗	Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study	Completed	University of Kentucky	Early Phase 1	2017-08-21	By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.

All Clinical Trials for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03707795 ↗	Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study	Completed	Edward Kasaraskis	Early Phase 1	2017-08-21	By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
NCT03707795 ↗	Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study	Completed	University of Kentucky	Early Phase 1	2017-08-21	By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements.
NCT04593706 ↗	Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)	Not yet recruiting	Tel-Aviv Sourasky Medical Center	N/A	2020-11-01	Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids and hypertrophic Scars)
NCT07297264 ↗	Betamethasone and Complications of Lower Third Molar Surgery	TERMINATED	Shehab Ahmed Hamad	PHASE3	2022-01-03	Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae

Clinical Trial Conditions for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Condition Name

Condition Name for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Intervention	Trials
Hypertrophic Scar	1
Keloid	1
Morbidity	1
Scarring	1

Condition MeSH

Condition MeSH for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Intervention	Trials
Hypertrophy	1
Cicatrix, Hypertrophic	1
Cicatrix	1
Motor Neuron Disease	1

Clinical Trial Locations for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Trials by Country

Trials by Country for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Location	Trials
Iraq	1
United States	1

Trials by US State

Trials by US State for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Location	Trials
Kentucky	1

Clinical Trial Progress for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Clinical Trial Phase

Clinical Trial Phase for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Clinical Trial Phase	Trials
PHASE3	1
N/A	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Clinical Trial Phase	Trials
Not yet recruiting	1
TERMINATED	1
Completed	1

Clinical Trial Sponsors for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Sponsor Name

Sponsor Name for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Sponsor	Trials
Edward Kasaraskis	1
University of Kentucky	1
Tel-Aviv Sourasky Medical Center	1

Sponsor Type

Sponsor Type for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Sponsor	Trials
Other	4

Betamethasone Acetate and Betamethasone Sodium Phosphate: Clinical Trial Update, Market Analysis and Projection

Last updated: April 25, 2026

What is this drug and how is it marketed?

Betamethasone acetate + betamethasone sodium phosphate is a fixed combination of:

• Betamethasone acetate (depot component)
• Betamethasone sodium phosphate (soluble component)

It is used for the treatment of inflammatory conditions and is commonly delivered as injectable formulations (intermuscular, intra-articular, or local injection depending on product and indication). Multiple branded products exist globally, with labeling built around corticosteroid efficacy and safety for inflammatory disorders.

---

What clinical trial activity is observable and where is it concentrated?

A comprehensive, product-level clinical trial update requires trial-level identification tied to the exact combination (acetate + sodium phosphate) rather than the broader class “betamethasone.” Without a trial registry pull by formulation and route, the only safe statement is that clinical development for this specific combination is not a new pipeline, but rather a mature, label-driven use profile. The combination exists primarily as an approved injectable corticosteroid used in routine care, with sporadic studies typically aimed at:

• comparative pharmacodynamics (Dosing, onset, duration),
• formulation or administration technique,
• specific inflammatory indications (orthopedics, dermatology, rheumatology).

Actionable implication for R&D and investment: treat the combination as a mature asset class where the highest-value “clinical update” tends to be label expansion, new delivery approaches, or biosimilar/generic competitiveness, not novel mechanism-of-action development.

---

Which approvals and labeling realities matter for market access?

Across major markets, betamethasone injectable combinations are governed by:

• corticosteroid risk controls (infection risk, immunosuppression effects, contraindications),
• route-specific restrictions (intra-articular and other local use have distinct labeling),
• dose and duration conventions (short courses and intermittent use are standard practice for many indications).

These controls shape utilization and limit “unbounded growth.” Market penetration grows with:

• physician awareness,
• guideline inclusion by indication,
• and safety profile adherence in real-world settings.

---

Where does demand come from: which indications drive use?

Commercial use of injectable betamethasone acetate plus betamethasone sodium phosphate is concentrated in inflammatory conditions where rapid onset and sustained effect are clinically valued.

Typical demand channels include:

• musculoskeletal and orthopedic inflammation (e.g., bursitis, tendinitis, intra-articular inflammatory flares),
• rheumatologic inflammatory episodes (selected steroid-responsive indications),
• dermatologic inflammatory use (where injectable corticosteroids are used under clinician practice patterns),
• other steroid-responsive inflammatory conditions depending on country labeling and reimbursement.

The combination’s market role is usually symptom control and flare management, not curative treatment.

---

How big is the market and what does “mature category” imply for growth?

Exact dollar market size for “betamethasone acetate + betamethasone sodium phosphate” as a standalone SKU category depends on how analysts segment injectable corticosteroids. In practice, the combination trades within the broader injectable corticosteroids market that is driven by:

• chronic inflammatory prevalence,
• orthopedic and rheumatology procedure volume,
• substitution between steroid types,
• and payer dynamics around generics.

Mature asset implication: growth typically tracks modest volume effects (utilization and clinician adoption) plus inflationary or reimbursement shifts, with competitive pricing pressure from generics/biosimilars across corticosteroids.

Investment read-through:

• Expect pricing compression over time where generic competition is strong.
• Expect volume stability where the combination is entrenched in standard of care and administered in outpatient and procedure settings.

---

What are the competitive dynamics (generic vs branded) that shape price?

For betamethasone injectable combinations, the competitive set generally includes:

• generic versions of the same active combination,
• other corticosteroid injectables with different depot/solubility profiles,
• and alternative delivery systems (different steroids, different formulation types).

Key competitive variables:

• acquisition cost per dose,
• perceived duration/onset performance (clinician preference),
• formulary access and rebate structures,
• and switching friction (procedural habits, local stock availability).

This combination’s differentiator is pharmacokinetic design (soluble plus depot steroid), but in a mature class, clinical practice often normalizes to the lowest-cost stocked product.

---

What regulatory and safety factors cap upside?

Corticosteroids impose recurring utilization constraints:

• infection risk and screening requirements,
• contraindications for active severe infections,
• caution for immunocompromised patients,
• peri-administration safety protocols for local injections (e.g., intra-articular precautions).

These constraints reduce “addressable growth” compared with specialty biologics or oncology drugs, because corticosteroid use is bounded by risk-benefit and clinical guidelines.

---

Market projection: base case, bull case, bear case

Without a cited, trial-linked data pull for the exact combination SKU and without a cited market sizing methodology specific to this formulation, a projection must remain mechanistic and scenario-based rather than numeric. Below are structured projections framed by what actually moves revenue in mature injectable steroid categories.

Base case (most likely for a mature combination)

• Volume: stable to low single-digit growth driven by procedure volume and clinician use patterns.
• Price: gradual erosion from competitive sourcing.
• Revenue trend: modest growth or flat-to-low growth.

Bull case

• Volume uplift from guideline reinforcement and expanded local practice uptake.
• Formulary wins in key hospital systems.
• Revenue grows faster than category pricing erosion, leading to mid single-digit growth.

Bear case

• Accelerated price compression from additional generic entry or aggressive tendering.
• Utilization substitution toward alternative corticosteroids or non-steroid pathways.
• Revenue declines or stagnates.

Actionable insight: for planning, treat betamethasone acetate + betamethasone sodium phosphate as a defensive cash-flow category where upside comes primarily from contracting/formulary positioning, not from blockbuster-grade innovation.

---

What is the investment-grade view of pipeline and R&D ROI?

Given the maturity and established role, ROI is typically driven by:

• product lifecycle management (supply reliability, improved manufacturing, low cost per unit),
• regulatory maintenance and line extensions (route-specific or indication-specific updates),
• and incremental clinical support that improves label robustness or payer acceptance.

High-cost mechanism innovation is unlikely to reset the competitive landscape because the mechanism is already well understood and clinically entrenched.

---

Key Takeaways

• Betamethasone acetate + betamethasone sodium phosphate is a mature, depot-plus-soluble injectable corticosteroid combination used for steroid-responsive inflammatory indications.
• Clinical trial activity specific to the exact combination is not a primary growth driver; updates tend to be incremental (comparative performance, administration technique, or indication-specific label support).
• Market growth is bounded by corticosteroid safety controls and standard-of-care substitution, so revenue performance depends mainly on formulary access, pricing dynamics, and procedure volume.
• Projections should be scenario-based: base case is stable to modest growth with pricing pressure, bull case requires formulary wins and volume uplift, and bear case is driven by faster generic or tender-driven price erosion.

---

FAQs

1) Is this combination considered a new mechanism pipeline?
No. It is a mature corticosteroid formulation with established clinical use patterns.

2) What drives demand most: indication prevalence or trial innovation?
Demand typically tracks inflammatory burden plus procedure volume and clinician practice, not mechanism-changing trial outcomes.

3) What is the main commercial risk?
Price compression and substitution within injectable corticosteroids due to generic competition and tender behavior.

4) What is the main commercial opportunity?
Formulary adoption and contracting, plus any label reinforcement in high-volume indications.

5) How should investors treat clinical trial updates for this drug?
As supportive for lifecycle management rather than as a proxy for major market expansion.

---

References

[1] Drugs.com. Betamethasone Acetate and Betamethasone Sodium Phosphate Injection (Betamethasone Acetate and Betamethasone Sodium Phosphate) information. https://www.drugs.com
[2] U.S. Food and Drug Administration. Drug safety communications and label information for corticosteroids (general class labeling resources). https://www.fda.gov
[3] European Medicines Agency. Human medicine product information for corticosteroids (general reference resources). https://www.ema.europa.eu